Scientific Abstracts
AB0406 STABLE EFFICACY AND SAFETY AFTER SWITCHING FROM TOCILIZUMAB INTRAVENOUS TO SUBCUTANEOUS IN RHEUMATOID ARTHRITIS: RESULTS OF A COHORT OF 200 PATIENTS
The objectives were to evaluate the efficacy maintenance (maintenance rate and DAS28 variation), the safety, the dose variation after the switch and the characteristics of patients switching to the subcutaneous form respect to those following with the intravenous tocilizumab. Methods: Multicenter and retrospective study was performed from a cohort of 203 patients undergoing intravenous tocilizumab from the rheumatology unit of 7 university hospitals between September 2015 and May 2016. Assessment has been done on the records, effectiveness was assessed using the DAS28, adverse events and reasons for staying on IV form were reported.
Results: On the 203 records analyzed, 3 were secondarily excluded. Of the 200 patients, 77 have switched for the subcutaneous form. Mean age of the 200 patients was 58 years (+/-13.3) with 155 women (78%) and the mean duration of rheumatoid arthritis was 14 years (+/-10.4). 72% of patients received a standard intravenous dose (8mg/kg/month) at baseline. At the first visit after the prescription of the subcutaneous treatment, 58 patients on 65 (89%) maintained the treatment. The mean DAS28 was 1.53 (+/-1.00) at baseline and 1.19 (+/-0.78) at T1 (45 patients). Three patients received a reduced subcutaneous dose of 162mg/2 weeks following a reduced IV dose (<8 mg/kg/month) and maintained the subcutaneous treatment. About safety, there was no new case of neutropenia<1000/mm 3 . One severe adverse effect occurred (gastro intestinal perforation). Regard to the dose variation, for the 77 patients switching, the mean difference between intravenous and subcutaneous dose was + 29mg/week (+/-35mg) with the subcutaneous tocilizumab. Reasons for staying on IV form were essentially: the subcutaneous tocilizumab was not proposed in 55% of the cases and 17% of patients refused the subcutaneous form. Conclusions: 89% of patients maintained the subcutaneous treatment after 4 months; efficacy was maintained in patients who received a reduced subcutaneous dose. Despite the higher dose after the switch (+29mg/week), there was no new case of neutropenia. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.6008 Methods: Eligible participants were TCZ-naïve patients from the Corrona RA registry who had prior exposure to ≥1 TNFi, initiated TCZ mono or a TNFi + MTX between 2010 and 2016 and had a 6-month follow-up visit. The primary outcome was mean change from baseline in Clinical Disease Activity Index (CDAI) at 6 months. Secondary outcomes included achievement of low disease activity (LDA; CDAI ≤10) at 6 months. Patients initiating a TNFi + MTX were grouped by MTX dose (≤10 mg; >10 to ≤15 mg; >15 to ≤20 mg; >20 mg); outcomes in each group were compared with those initiating TCZ mono using trimmed populations, excluding patients outside the propensity score (PS) distribution overlap (not on common support). The PS included age, sex, race, body mass index, smoking status, work status, disease duration, concomitant prednisone use/dose, prior biologic use, American College of Rheumatology functional class and baseline modified Health Assessment Questionnaire, CDAI and patient pain scores. As a sensitivity analysis, stratified-matched populations were created (stratified by 1 vs ≥2 prior biologics, then matched on PS). Linear and logistic regression models were estimated in the trimmed populations, adjusting for the same covariates as in the PS. Results: Baseline demographics were generally comparable between the TNFi + MTX groups and their matched TCZ mono groups. Overall, the mean age was 54 to 59 years, and the mean disease duration was 10.5 to 15 years. A higher proportion of patients initiating TCZ mono had received ≥3 prior biologics compared with those initiating TNFi + MTX. Patients initiating TCZ mono had significantly longer mean disease duration than those initiating TNFi + MTX >15 to ≤20 mg (13.0 vs 10.5 years) or TNFi + MTX >20 mg (12.3 vs 9.3 years) and a higher mean baseline CDAI than those initiating TNFi + MTX ≤10 mg (28.1 vs 25.4). Patients in all groups had improvement in CDAI scores at 6 months. In adjusted models, improvement in CDAI and the likelihood of achieving LDA were similar between the TCZ mono group and all TNFi + MTX groups (Table) . Similar results were observed in the PS-matched cohorts. Conclusions: TCZ mono was as effective as TNFi + MTX, regardless of MTX dose, for improving disease activity in patients with prior TNFi exposure. These data suggest that TCZ mono is an effective treatment option for patients with RA who cannot tolerate or prefer not to use MTX.
AB0407 COMPARATIVE EFFECTIVENESS OF TOCILIZUMAB (TCZ) MONOTHERAPY WITH TUMOR NECROSIS FACTOR INHIBITORS (TNFI) IN COMBINATION WITH VARYING DOSES OF METHOTREXATE (MTX) IN PATIENTS WITH RHEUMATOID ARTHRITIS

